Colgate Q4 Results Review: ICICI Securities Downgrades To 'Sell', Sees 32% Potential Downside — Here's Why

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 

ICICI Securities Report

We've been long critical of Colgate Palmolive India Ltd.'s (consistent) strategy of-

1. not investing (enough) for toothpaste category growth (our opinion),

2. not aggressive (enough) in diversifying outside of oralcare (parent has a good home and personal care portfolio though),

3. over-earning, in our opinion (operating margins at ~37% after adding back royalty).

Disappointing Q4 FY25 is just the beginning (revenue declined 2% YoY) of a prolonged winter. In the near-past, it has pursued a price-hike driven revenue growth strategy, which we have always believed to be unsustainable (reminds us of ~2010 era in Nestle India).

At 45x FY27E P/E, we reckon stock has the potential to derate (further meaningfully) to 30x, despite 12% underperformance vs Nifty (last 12 months).

Downgrade to Sell (from Hold) with a target price of Rs 1,800.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.